Holen Sie sich die Stockscreener-App
74.45
6.20%
-4.92
Handel nachbörslich:
74.39
-0.06
-0.08%
Schlusskurs vom Vortag:
$79.37
Offen:
$77.6
24-Stunden-Volumen:
2.54M
Relative Volume:
1.93
Marktkapitalisierung:
$7.85B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
59.09
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
+36.28%
1M Leistung:
+32.97%
6M Leistung:
+63.88%
1J Leistung:
+197.21%
1-Tages-Spanne:
$72.59
$78.00
1-Wochen-Bereich:
$72.59
$117.33
52-Wochen-Spanne:
$20.84
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
74.45 | 7.85B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada
Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com India
Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com India
Corcept therapeutics president sells shares worth $10.1 million - Investing.com
Corcept therapeutics officer sells $20.2 million in stock - Investing.com
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance
Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - Yahoo Finance
Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Yahoo Finance
Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com
Here's Why Momentum in Corcept (CORT) Should Keep going - Yahoo Finance
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? - Yahoo Finance
Corcept Therapeutics Reaches Analyst Target Price - Nasdaq
Corcept Therapeutics Shares Surge 109% to $114.22 on Phase 3 Trial Breakthrough - TradingPedia
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement - Yahoo Finance
HC Wainwright Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
AIG, Corcept Therapeutics, Dow - TradingView
Truist Financial Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up After Analyst Upgrade - Defense World
Why Corcept Therapeutics (CORT) Stock Skyrocketed Today - GuruFocus
Corcept Therapeutics (CORT) Shares Skyrocket Amid Clinical Trial Success - GuruFocus
Corcept Therapeutics shares double on solid Phase 3 results for ovarian cancer treatment - Mugglehead Magazine
Corcept Therapeutics stock soars to all-time high of $95.42 By Investing.com - Investing.com South Africa
Corcept looks to NDA following strong phase III ovarian cancer data - BioWorld MedTech
Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity - insights.citeline.com
Corcept (CORT) Shares Soar 95% on Positive Phase 3 Trial Results - GuruFocus
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) - Benzinga
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - BioSpace
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
Why Is Corcept (CORT) Stock Soaring Today - Yahoo Finance
Corcept’s ovarian cancer drug cuts disease progression in study, shares jump By Reuters - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip - simplywall.st
Corcept's ovarian cancer drug cuts disease progression in study, shares jump - Reuters
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute - Yahoo Finance
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer - Endpoints News
Corcept Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corcept Therapeutics Inc-Aktie (CORT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Maduck Sean | See Remarks |
Apr 01 '25 |
Option Exercise |
5.05 |
590 |
2,980 |
86,212 |
| Maduck Sean | See Remarks |
Mar 31 '25 |
Sale |
100.54 |
100,000 |
10,054,010 |
85,622 |
| Maduck Sean | See Remarks |
Apr 01 '25 |
Sale |
114.55 |
590 |
67,584 |
85,622 |
| Lyon Joseph Douglas | See Remarks |
Mar 31 '25 |
Option Exercise |
16.55 |
200,000 |
3,309,400 |
209,009 |
| Lyon Joseph Douglas | See Remarks |
Apr 01 '25 |
Option Exercise |
13.56 |
650 |
8,814 |
9,659 |
| Lyon Joseph Douglas | See Remarks |
Mar 31 '25 |
Sale |
100.47 |
200,000 |
20,093,511 |
9,009 |
| Lyon Joseph Douglas | See Remarks |
Apr 01 '25 |
Sale |
114.53 |
650 |
74,443 |
9,009 |
| Guyer William | Chief Development Officer |
Apr 01 '25 |
Option Exercise |
21.65 |
678 |
14,679 |
6,165 |
| Guyer William | Chief Development Officer |
Apr 01 '25 |
Sale |
114.51 |
678 |
77,639 |
5,487 |
| BELANOFF JOSEPH K | Chief Executive Officer |
Mar 31 '25 |
Sale |
94.72 |
35,102 |
3,324,861 |
2,982,335 |
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):